Carbonic anhydrase-IN-35 

Carbonic anhydrase-IN-35 is a selective carbonic anhydrase (CA) inhibitor. Carbonic anhydrase-IN-35 potently inhibits tumor-associated hCA IX (K_i = 0.6 nM) and hCA XII (K_i = 2.2 nM). Carbonic anhydrase-IN-35 induces apoptosis in MCF-7 cells by elevating Bax, reducing Bcl-2, and downregulating CDK4/6. Carbonic anhydrase-IN-35 exhibits potent cytotoxicity against MCF-7 (IC₅₀ = 0.3975 μM normoxic/0.6575 μM hypoxic), MCF-7-ADR (IC_{50> = 0.3975 μM normoxic/4.488 μM hypoxic), MDA-MB-231, and 4T1 breast cancer cells. Carbonic anhydrase-IN-35 can be used for the study of breast cancer^[1].}

Carbonic anhydrase-IN-35 (Compound 10a) exhibits potent inhibitory activity against tumor-associated hCA IX (K_i = 0.6 nM), hCA XII (K_i = 2.2 nM), hCA I (K_i = 6183 nM) and hCA II (K_i = 12.7 nM)^[1].
Carbonic anhydrase-IN-35 shows potent cytotoxicity against MCF-7 cells under normoxic conditions (IC₅₀ = 0.3975 μM) and hypoxic conditions(IC₅₀ = 0.6575 μM)^[1].
Carbonic anhydrase-IN-35 shows potent cytotoxicity against MCF-7-ADR breast cancer cells under normoxic conditions (IC₅₀ = 0.3975 μM) and hypoxic conditions(IC₅₀ = 4.488 μM)^[1].
Carbonic anhydrase-IN-35 shows potent anti-proliferative activity against MDA-MB-231 triple-negative breast cancer cells with an IC₅₀ of 1.9 μM and against 4T1 triple-negative breast cancer cells with an IC₅₀ of 2.38 μM^[1].
Carbonic anhydrase-IN-35 (24 h) increases the expression of pro-apoptotic Bax, downregulates anti-apoptotic Bcl-2 and CDK4/6 in MCF-7 breast cancer cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

400.41

C₁₇H₁₆N₆O₄S

O=S(C1=CC=C(N2N=NC(C(N/N=C/C3=CC=C(O)C=C3)=O)=C2C)C=C1)(N)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ibrahim MH, et al. Sulfonamide-arylidene hybrids featuring flexible hydrazide and rigid triazole linkers: design, synthesis, and evaluation as carbonic anhydrase inhibitors with anti-breast cancer potential. Bioorg Chem. 2025 Jul 29;164:108803.